Informed consent and contraception when prescribing valproate to individuals of childbearing potential: a quality improvement project
- 15 January 2026
- journal article
- research article
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (1) , 18
Abstract
Purpose Valproate is an efficacious treatment for several neurologic and psychiatric disorders, but it carries a grave risk of teratogenicity. Despite warnings from regulatory bodies, prescribing guidelines from professional associations, and expert opinion against the practice, the medication continues to be commonly prescribed to persons with childbearing potential for psychiatric indications. Methods A quality improvement focused educational intervention on the conduct and documentation of informed consent and contraceptive counseling when prescribing the teratogen valproate to individuals aged 12–55 who may become pregnant was implemented in the Psychiatry Department of an urban community hospital. Documentation from 3 months before and after the intervention was qualitatively assessed for notation of informed consent, including the patient’s expressed understanding of risks as well as specific counseling on teratogenicity and the need for contraception, in acute care and outpatient charts that had a prescription from a psychiatric provider for valproate in that time frame. Results While statistically significant improvement was found in the documentation of general informed consent and patients’ responses to counseling in outpatient charts, there was no improvement in acute care charts and no significant increase in valproate-specific counseling in charts from either care setting. Conclusion The minimal impact of an educational initiative on documentation of informed consent in the present study suggests that education alone may not be sufficient to address the crucial safety concern of valproate prescribing practices in psychiatric patients who may become pregnant.Keywords
This publication has 34 references indexed in Scilit:
- Off-Label Use of Sodium Valproate for SchizophreniaPLOS ONE, 2014
- Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy RegistersJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood AutismJAMA, 2013
- Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational studyThe Lancet Neurology, 2013
- The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugsJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Antiepileptics for aggression and associated impulsivityCochrane Database of Systematic Reviews, 2010
- Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive useNeurology, 2009
- Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: Randomized, double-blind placebo-controlled studyEuropean Psychiatry, 2008
- Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.2001
- Epidemiology of isotretinoin exposure during pregnancyJournal of the American Academy of Dermatology, 1992